Fresenius acquire APP
Fresenius will acquire APP Pharmaceuticals, the US manufacturer of intravenous drugs, for $3.7 billion (£1.9 billion) in a deal that will help the German dialysis specialist break into the American market.
APP, the second-largest maker of intravenous generic drugs in the United States, will complement Fresenius’ Kabi unit, a global supplier of infusions and gastric tube feeding equipment, which so far has lacked a U.S. presence.
APP shareholders will receive $23 a share in cash, a 29 per cent premium to the last closing share price.
Follow the link for the full story in the Times or here for Forbes.
Other stories
Add IVTEAM to Technorati Favorites






Comments
Please leave a comment?